<DOC>
	<DOCNO>NCT01129856</DOCNO>
	<brief_summary>The purpose study assess safety efficacy EGP-437 ( dexamethasone phosphate formulate ocular iontophoresis ) use EyeGateÂ® II Iontophoresis system patient dry eye .</brief_summary>
	<brief_title>Safety Efficacy Study EGP-437 ( Dexamethasone Phosphate Formulated Ocular Iontophoresis ) Treat Dry Eye</brief_title>
	<detailed_description>Dry eye prevalent form ocular discomfort irritation . Estimates range 20 million people United States affect mild moderate dry eye , many one every five Americans . EyeGate complete single-center , randomize , double-masked , placebo-controlled Phase 2 efficacy study 105 subject mild moderate dry eye disease , utilize Controlled Adverse Environment ( CAE ) , clinical model allow standardize measurement dry eye sign symptoms investigation therapeutic agent . In Phase 2 study , improvement document dry eye sign symptom relative placebo group indicate ocular iontophoresis treatment EGP-437 ( dexamethasone phosphate formulate ocular iontophoresis ) rapid onset action long-term effectiveness . The Phase 3 study intend confirm extend result Phase 2 study , utilize CAE model . The study design assess safety efficacy EGP-437 two different dose level : Ocular Iontophoresis EGP-437 4.0 mA-min 1.5 mA Ocular Iontophoresis EGP-437 6.5 mA-min 2.5 mA compare Ocular Iontophoresis placebo ( sodium citrate buffer solution ) treatment sign symptom dry eye .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Have report history dry eye eye Be least 12 year age Demonstrate response expose Controlled Adverse Environment model Visits 1 2 Have contraindication use test article Have know allergy sensitivity study medication component Have ocular infection , active ocular inflammation , preauricular lymphadenopathy Be current contact lens wearer wear contact study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>Keratoconjunctivitis sicca</keyword>
	<keyword>Iontophoresis</keyword>
	<keyword>Ophthalmic drug delivery</keyword>
	<keyword>EGP-437</keyword>
	<keyword>Dexamethasone phosphate</keyword>
</DOC>